MAGNITUDE: A Phase 3 Study of NTLA-2001 in Participants With Transthyretin Amyloidosis With Cardiomyopathy (ATTR-CM)
Trial details
- Registry ID
- NCT06128629
- Drugs studied
- NTLA-2001
TrialRedline tracks 3 clinical trials sponsored by Intellia Therapeutics: 3 Phase 3.
Company identity has not yet been verified
| Trial | Drugs studied | Status | Primary completion |
|---|---|---|---|
| MAGNITUDE: A Phase 3 Study of NTLA-2001 in Participants With Transthyretin Amyloidosis With Cardiomyopathy (ATTR-CM)NCT06128629 | NTLA-2001 | Recruiting | 2027-12Estimated |
| A Phase 3 Study of NTLA-2001 in ATTRv-PNNCT06672237 | nexiguran ziclumeran | Active not recruiting | 2027-07Estimated |
| HAELO: A Phase 3 Study to Evaluate NTLA-2002 in Participants With Hereditary Angioedema (HAE)NCT06634420 | NTLA-2002, Normal Saline IV Administration | Active not recruiting | 2026-02-10Actual |
Names as written in the registry records.
NCT06672237 · Intellia Therapeutics
Before: Estimated. After: Actual.
Before: 60 participants (planned). After: 67 participants (actual).
Before: Recruiting. After: Active not recruiting.
NCT06634420 · Intellia Therapeutics
Before: Estimated. After: Actual.
Before: 60 participants (planned). After: 80 participants (actual).
Before: Estimated. After: Actual.
Before: Apr 2026. After: 10 Feb 2026.
NCT06672237 · Intellia Therapeutics
Before: 50 participants (planned). After: 60 participants (planned).
Before: Active not recruiting. After: Recruiting.
NCT06128629 · Intellia Therapeutics
Before: Active not recruiting. After: Recruiting.
NCT06128629 · Intellia Therapeutics
Before: 765 participants (planned). After: 1200 participants (planned).
Before: Recruiting. After: Active not recruiting.
NCT06672237 · Intellia Therapeutics
Before: Recruiting. After: Active not recruiting.